Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Marimed (MRMD) Equity Average (2016 - 2025)

Historic Equity Average for Marimed (MRMD) over the last 15 years, with Q3 2025 value amounting to $56.4 million.

  • Marimed's Equity Average fell 1735.14% to $56.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.4 million, marking a year-over-year decrease of 1735.14%. This contributed to the annual value of $64.2 million for FY2024, which is 97.23% up from last year.
  • Marimed's Equity Average amounted to $56.4 million in Q3 2025, which was down 1735.14% from $58.8 million recorded in Q2 2025.
  • Over the past 5 years, Marimed's Equity Average peaked at $80.4 million during Q3 2023, and registered a low of $11.4 million during Q1 2021.
  • Its 5-year average for Equity Average is $53.7 million, with a median of $58.8 million in 2025.
  • Its Equity Average has fluctuated over the past 5 years, first surged by 148230.98% in 2021, then plummeted by 1735.14% in 2025.
  • Over the past 5 years, Marimed's Equity Average (Quarter) stood at $35.8 million in 2021, then soared by 52.49% to $54.6 million in 2022, then surged by 37.17% to $74.9 million in 2023, then decreased by 15.62% to $63.2 million in 2024, then fell by 10.78% to $56.4 million in 2025.
  • Its Equity Average was $56.4 million in Q3 2025, compared to $58.8 million in Q2 2025 and $58.9 million in Q1 2025.